Trial intelligence / Profile preview

Dexmedetomidine in Asthma Patients Undergoing General Anesthesia

NCT02289391Phase 4

Key facts

Status: Unknown
Start: Dec 2014
Primary completion: Dec 2015
Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
Modality: Small Molecules

Drugs: dexmedetomidine
Conditions: asthma

Overview

Phase 4, randomised, double-blind trial of dexmedetomidine in asthma (4 arms), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Interleukin-4, Interleukin-5 and 6 more. Status: unknown.

Design

4 arms

Study design: RandomizedDouble-blind

Non-asthma Group
Patients without asthma receiving saline and standard anesthesia.
Dexmedetomidine A
Asthma patients receiving dexmedetomidine (0.4 μg/kg/h maintenance) and standard anesthesia.
Dexmedetomidine B
Asthma patients receiving dexmedetomidine (0.7 μg/kg/h maintenance) and standard anesthesia.
Control Group
Asthma patients receiving saline and standard anesthesia.

Who it enrols

Adult patients (18-65) with ASA I-II undergoing elective general anesthesia surgery, including 20 patients with a history of asthma and 60 patients without a history of asthma.

Endpoints

Primary

Interleukin-4
Interleukin-5
Interleukin-13
Interleukin-17
Interleukin-33

Secondary

Mean Arterial Pressure
Heart Rate
Respiratory Rate

Beyond the preview

Go deeper on NCT02289391.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02289391.